Novartis [clinicaltrials_resource:4b711ffdbe8af5c8f3f9c53da46d83fa]
Novartis US [clinicaltrials_resource:017f8f9a1798b6309e7bdffbfc684929]Novartis Vaccines Information Service +41 61 324 1111 [clinicaltrials_resource:03263b5ba10eaf2d6f6e9c5ca8f1f76e]NOVARTIS [clinicaltrials_resource:0f50762429bac2199de1fd2d0011e07b]Study Director [clinicaltrials_resource:19405e141e6b051665846c13aa9e5d6f]Novartis Pharmaceuticals Japan [clinicaltrials_resource:1be95cd7f9aae7d21d771cd6486dc0fe]Novartis Biociências S.A [clinicaltrials_resource:256c324e7352dd0a31d0b63dcdd9dbb0]Novartis Investigator Site [clinicaltrials_resource:2810c2aa37e2c34201ae7cb4ac1dee5f]Novartis Pharma AG [clinicaltrials_resource:2ddf9965778d57d03352d24dafe8617d]Novartis Biociências SA - Brazil [clinicaltrials_resource:2e81e543294f0a86132b65531c9a15f1]Novartis Vaccines [clinicaltrials_resource:364dd0c2a51d5e6dc4d0647ddc59dc96]Scott L. Pescatore, PharmD. [clinicaltrials_resource:38a1a8d69ce61570527c80f0c0fe4a1d]Jennifer Hedrick, MBA [clinicaltrials_resource:3b27daf7b7191a5e0c02a38463524340]Novartis . [clinicaltrials_resource:3efaf60c69ae54d91079009693918dd1]Novartis Vaccines and Diagnostics [clinicaltrials_resource:3fe64e6f718a9c396a6fb97b384eb66c]Novartis Pharmaceuticals [clinicaltrials_resource:4e4919bc17e514375b775f58e171dffc]Novartis Vaccines - Drug Information Services [clinicaltrials_resource:54c00ba43bc10b2c9b126e986b0538c3]Novartis [clinicaltrials_resource:57b29bd841bef7b1bebf634fa9f506cb]Novartis Pharmaceuticals [clinicaltrials_resource:6020e059b00fb1e889bbd10922fcbc5e]Novartis 862-778-8300 Pharmaceuticals [clinicaltrials_resource:658e17b1b16a55fa6deeaaf800027f0a]Novartis Vacccines and Diagnostics [clinicaltrials_resource:6a5e27d23e45265c28f12a2f403704ce]Novartis [clinicaltrials_resource:6f2d4fc54fb25602a33e239b65a68c25]Novartis AG [clinicaltrials_resource:709655bbecb14ebb2f313bf0570001e3]Novartis Pharmaceuticals [clinicaltrials_resource:719f9b4081799307452e1840561f1530]Novartis +41 61 324 1111 [clinicaltrials_resource:759e3189fee4dde25dfa346e480162c8]Novartis Vaccines - Drug Information Services [clinicaltrials_resource:7644b7b973df7b25bde232c9c058c132]Novartis Pharnmaceuticals [clinicaltrials_resource:788bd48594eb061a0774e5db7b15264b]Novartis Pharma [clinicaltrials_resource:7b7c0973e87118b22f4c021dcd571da3]Novartis [clinicaltrials_resource:7cb942c6d0724183a592d4221f454201]Novartis Pharmaceuticals [clinicaltrials_resource:7d5edd87843e247e6778b5dc0711831e]Novartis Vaccines - Information Services [clinicaltrials_resource:87de57636913bc2ef5ea8649ae305292]Novartis Pharmaceuticals [clinicaltrials_resource:98f2acef43d617a15b2d5bcc62e8a9f8]Novartis Vaccines [clinicaltrials_resource:a6720541de6d5e057266b28ca00c4ecf]Novartis Vaccines and Diagnostics [clinicaltrials_resource:a7684e66a5191967827a75bc10841b49]Customer Information [clinicaltrials_resource:b0ab4ff5b59a9b4173c18dbcd0f6ac04]Novartis Pharmcuticals [clinicaltrials_resource:b3093ac6b8694593fab79da5dae01e45]Novartis Customer Information [clinicaltrials_resource:bb3fe19476f34671f62ebb37ee3adf18]Novartis Vaccine and Diagnostics [clinicaltrials_resource:c99df915735e464053e55a8e243dda58]Novartis Vaccines [clinicaltrials_resource:ccaf30854a25de79999912905fa65541]Novartis Drug Information Services +1 800 244 7668 [clinicaltrials_resource:d042f5cc0cf307a7a0155a364a58f3df]NVGH [clinicaltrials_resource:d2ed1066954e3348a451129e9fada750]
affiliation [clinicaltrials_vocabulary:affiliation]
STI571 Compared With Interferon Alfa Plus Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia [clinicaltrials:NCT00006343]Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Metastatic Colorectal Cancer. [clinicaltrials:NCT00056459]A Randomized, Double Blind Trial of LdT (Telbivudine) Versus Lamivudine in Adults With Compensated Chronic Hepatitis B [clinicaltrials:NCT00057265]Telbivudine Versus Adefovir Dipivoxil in Adults With HBegAg-Positive, Compensated Chronic Hepatitis B [clinicaltrials:NCT00115245]An Extension Study of Telbivudine, Lamivudine or Telbivudine Plus Lamivudine in Patients With Chronic Hepatitis B [clinicaltrials:NCT00124241]Using Behavioral Therapy in Combination With Darifenacin for Symptoms of Overactive Bladder [clinicaltrials:NCT00127270]Telbivudine Versus the Combination of Telbivudine and Valtorcitabine in Patients With Chronic Hepatitis B [clinicaltrials:NCT00128544]A 3-week Study Investigating Patient Use and Functionality of Formoterol in a Novel Inhalation Device in Patients With Asthma [clinicaltrials:NCT00130351]Telbivudine Versus Lamivudine in Chinese Adults With Compensated Chronic Hepatitis B [clinicaltrials:NCT00131742]Switching Therapy From Lamivudine to Telbivudine Versus Continued Lamivudine in Adults With Chronic Hepatitis B [clinicaltrials:NCT00132652]Ketotifen Ophthalmic Solution With Emedastine in Patients With Seasonal Allergic Conjunctivitis [clinicaltrials:NCT00133627]Photodynamic Therapy in Occult-Only Lesions (POOL) [clinicaltrials:NCT00135837]Efficacy, Safety, and Tolerability of Darifenacin in Patients Aged > 65 Years With Overactive Bladder [clinicaltrials:NCT00171184]Fluvastatin in the Therapy of Acute Coronary Syndrome [clinicaltrials:NCT00171275]A Study Comparing the Response of Patients With Hypertension to Amlodipine or Amlodipine Plus Benazepril. [clinicaltrials:NCT00171366]Study of the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Effects of Vatalanib in Combination With Capecitabine in Patients With Advanced Cancer [clinicaltrials:NCT00171587]Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases [clinicaltrials:NCT00219219]Long-Term Study of IGE025 in Moderate to Severe Bronchial Asthma. [clinicaltrials:NCT00219323]Study of Omalizumab in Moderate to Severe Bronchial Asthma [clinicaltrials:NCT00232050]Study of the Safety and Immune Response of a Meningococcal Vaccine Administered to Healthy Children [clinicaltrials:NCT00262028]clinicaltrials:NCT00264849clinicaltrials:NCT00267202The Effects of Tegaserod Vs. Placebo on Whole Gut Transit Time in Patients With Chronic Constipation and Dyspepsia [clinicaltrials:NCT00277550]Safety, Tolerability and Immunogenicity of Meningococcal C Conjugate Vaccine to Children 32 to 40 Months of Age [clinicaltrials:NCT00310635]Comparative Trial Evaluating Safety and Immunogenicity of an Adjuvanted and a Conventional Influenza Vaccine in Elderly Subjects (> 60 Years) [clinicaltrials:NCT00310648]Immunogenicity, Safety and Tolerability, of Chiron Meningococcal C Conjugate Vaccine Administered to Healthy Premature and Non Premature Children of 3 Months of Age [clinicaltrials:NCT00310674]Persistence of Immune Response After Vaccination With MCC [clinicaltrials:NCT00310687]Kinetics of B Cell Response in Infants Menjugate Vaccination [clinicaltrials:NCT00310700]Safety and Immunogenicity of Chiron Meningococcal ACWY Conjugate Vaccine in Healthy Children Aged 12-59 Months. [clinicaltrials:NCT00310817]Safety and Immunogenicity of Three Commercially Available Influenza Vaccines in Children Aged 6 to <36 Months [clinicaltrials:NCT00311428]Study of the Safety, Tolerability and Immune Response of TBE Vaccines Administered to Healthy Children [clinicaltrials:NCT00311441]Safety and Immunogenicity of Two Doses, Administered Three Weeks Apart, of Two(Surface Antigen Adjuvanted With MF59C.1) Influenza Vaccines in Non-Elderly Adult and Elderly Subjects [clinicaltrials:NCT00311480]Evaluation of Long-Term Immunogenicity in Subjects Boosted With a TBE Vaccine for Adults [clinicaltrials:NCT00311493]Safety and Immunogenicity of a Inactivated Influenza Vaccine When Administered to Non Elderly Adults and Elderly Subjects. [clinicaltrials:NCT00316615]Safety and Immunogenicity of an Adjuvanted Influenza Vaccine in Subjects Aged 65 Years and Over. [clinicaltrials:NCT00316628]Persistence of Antibody Response to N. Meningitidis Group C in Children [clinicaltrials:NCT00316654]Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2006/2007) When Administered to Elderly Subjects [clinicaltrials:NCT00329927]Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2006/2007) When Administered to Subjects 18 Years of Age or Older [clinicaltrials:NCT00329966]Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2006/2007) When Administered to Subjects 18 Years of Age or Older [clinicaltrials:NCT00342940]Effect of Tegaserod on Orocecal Transit in Elderly Chronic Constipation Patients [clinicaltrials:NCT00348634]
collaborator [clinicaltrials_vocabulary:collaborator]
Investigation Into Delay to Diagnosis of Alzheimer's Disease With Exelon (InDDEx) [clinicaltrials:NCT00000174]Safety and Effectiveness of Giving Lamisil to HIV-Positive Subjects With Thrush Who Have Not Responded to Fluconazole Treatment [clinicaltrials:NCT00002394]Zoledronate in Treating Patients With Solid Tumors That Have Spread to the Bone [clinicaltrials:NCT00003884]STI571 in Treating Patients With Accelerated Phase Chronic Myelogenous Leukemia [clinicaltrials:NCT00006052]STI571 in Treating Patients With Chronic Myelogenous Leukemia That Has Not Responded to Interferon Alfa [clinicaltrials:NCT00006053]Octreotide in the Prevention of Diarrhea in Patients Receiving Irinotecan for Metastatic Colon Cancer [clinicaltrials:NCT00006269]STI571 Compared With Interferon Alfa Plus Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia [clinicaltrials:NCT00006343]STI571 in Treating Patients With Chronic Myelogenous Leukemia in Blast Crisis [clinicaltrials:NCT00006475]Letrozole in Treating Postmenopausal Women With Metastatic Breast Cancer [clinicaltrials:NCT00014638]Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions [clinicaltrials:NCT00029224]Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Metastatic Colorectal Cancer. [clinicaltrials:NCT00056459]A Randomized, Double Blind Trial of LdT (Telbivudine) Versus Lamivudine in Adults With Compensated Chronic Hepatitis B [clinicaltrials:NCT00057265]Sandostatin LAR® Depot in Patients With Primary Insulin Hypersecretion (PIH) and at Least Moderate Obesity [clinicaltrials:NCT00094146]Famciclovir Oral Pediatric Formulation in Children 1-12 Years of Age With Varicella Zoster Infection [clinicaltrials:NCT00098046]Follow-Up Study of Patients Previously Treated With Pimecrolimus Tablets for Atopic Dermatitis [clinicaltrials:NCT00098150]Follow-Up Study of Patients Previously Treated With Pimecrolimus Tablets for Chronic Plaque-Type Psoriasis [clinicaltrials:NCT00098189]Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease [clinicaltrials:NCT00099242]Study of the Effects of Current Drug Treatments on Levels of Certain Brain Chemicals in Alzheimer's Disease [clinicaltrials:NCT00104442]Telbivudine Versus Adefovir Dipivoxil in Adults With HBegAg-Positive, Compensated Chronic Hepatitis B [clinicaltrials:NCT00115245]Effects of Pimecrolimus Cream 1% on the Molecular and Cellular Profile of Adult Male Patients With Atopic Dermatitis [clinicaltrials:NCT00117377]Terbinafine Compared to Griseofulvin in Children With Tinea Capitis [clinicaltrials:NCT00117754]Quality of Life Study in Adults With Facial Eczema [clinicaltrials:NCT00120302]Efficacy and Safety of Three Doses of Vildagliptin in Drug Naive Patients With Type 2 Diabetes [clinicaltrials:NCT00120536]Safety and Efficacy of Pimecrolimus Cream 1% in Mild to Moderate Head and Neck Atopic Dermatitis (AD) Patients [clinicaltrials:NCT00121316]Pimecrolimus Cream 1% Plus Topical Corticosteroid in Patients (2-17 Years of Age) With Severe Atopic Dermatitis [clinicaltrials:NCT00121381]An Extension Study of Telbivudine, Lamivudine or Telbivudine Plus Lamivudine in Patients With Chronic Hepatitis B [clinicaltrials:NCT00124241]Fluvastatin in Adults With Dislipidemia With History of Muscle Problems [clinicaltrials:NCT00125125]Tobramycin Inhalation Powder (TIP) in Cystic Fibrosis Subjects [clinicaltrials:NCT00125346]Using Behavioral Therapy in Combination With Darifenacin for Symptoms of Overactive Bladder [clinicaltrials:NCT00127270]Safety and Efficacy of Octreotide Long Acting Release (LAR) in Treatment Naïve Acromegalic Patients [clinicaltrials:NCT00128232]Safety and Efficacy of Pimecrolimus Ophthalmic Suspension in Patients With Moderate to Severe Keratoconjunctivitis Sicca [clinicaltrials:NCT00128245]Telbivudine Versus the Combination of Telbivudine and Valtorcitabine in Patients With Chronic Hepatitis B [clinicaltrials:NCT00128544]A Study to Evaluate the Effect of Famciclovir in Reducing Herpes Virus Shedding [clinicaltrials:NCT00129818]Study to Assess the Safety and Tolerability of Incremental Doses of QAB149 in Adults With Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD) [clinicaltrials:NCT00129831]Rivastigmine Capsules in Patients With Probable Vascular Dementia [clinicaltrials:NCT00130338]A 3-week Study Investigating Patient Use and Functionality of Formoterol in a Novel Inhalation Device in Patients With Asthma [clinicaltrials:NCT00130351]Efficacy and Safety of Pimecrolimus Cream 1% in Patients (2 to 11 Years Old) With Mild to Moderate Facial Atopic Dermatitis [clinicaltrials:NCT00130364]Octreotide Acetate in Microspheres in Patients With Diabetic Retinopathy [clinicaltrials:NCT00130845]Octreotide Acetate in Microspheres in Patients With Diabetic Retinopathy [clinicaltrials:NCT00131144]Telbivudine Versus Lamivudine in Chinese Adults With Compensated Chronic Hepatitis B [clinicaltrials:NCT00131742]
lead sponsor [clinicaltrials_vocabulary:lead-sponsor]
Novartis Vaccines and Diagnostics s.r.l., Novartis [clinicaltrials_resource:0da70b4c849392c313b0a6babae65373]External Affairs, Novartis [clinicaltrials_resource:213cdf590d7c385c6ac3d32633a077e1]Study director, Novartis [clinicaltrials_resource:585a252022eab03c5def9ab0ba63a698]Novartis, Novartis [clinicaltrials_resource:6d8c029072ce4da24caccc964c0f4d1f]Head, New Therapeutic Opportunities, Novartis [clinicaltrials_resource:74cdbfa428c6e93bd59926bc19111f96]Regulatory Affairs, Novartis [clinicaltrials_resource:9379c98b8b8dd4903ca6d872c442bbe2]Novartis Pharmaceuticals, Novartis [clinicaltrials_resource:979b586b8fc4d360a1e3d2a64306ebd0]Novartis Pharmaceuticals, Japan, Novartis [clinicaltrials_resource:9c1369532498ef5d747ddb5c47145f4a]external affairs, Novartis [clinicaltrials_resource:c30ab6ed7f589a6fc8f6d1c2eadbf828]External affairs, Novartis [clinicaltrials_resource:d9f3f9f69cfe315c72b0c67a5abe1a08]Novartis Vaccines and Diagnostics, Novartis [clinicaltrials_resource:ffbb26e8a5d1affd190772212ecc022b]
organization [clinicaltrials_vocabulary:organization]
Zoledronate in Treating Patients With Solid Tumors That Have Spread to the Bone [clinicaltrials:NCT00003884]Zoledronate Plus Standard Therapy Compared With Placebo Plus Standard Therapy to Prevent Bone Metastases in Patients With Recurrent Prostate Cancer That Has No Symptoms [clinicaltrials:NCT00005073]STI571 in Treating Patients With Accelerated Phase Chronic Myelogenous Leukemia [clinicaltrials:NCT00006052]STI571 in Treating Patients With Chronic Myelogenous Leukemia That Has Not Responded to Interferon Alfa [clinicaltrials:NCT00006053]Octreotide in the Prevention of Diarrhea in Patients Receiving Irinotecan for Metastatic Colon Cancer [clinicaltrials:NCT00006269]STI571 Compared With Interferon Alfa Plus Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia [clinicaltrials:NCT00006343]Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer [clinicaltrials:NCT00006368]Radiolabeled SMT-487 (Yttrium Y 90-DOTA-tyr3-octreotide) in Treating Patients With Refractory Small Cell Lung Cancer or Metastatic Breast Cancer [clinicaltrials:NCT00006370]STI571 in Treating Patients With Chronic Myelogenous Leukemia in Blast Crisis [clinicaltrials:NCT00006475]Letrozole in Treating Postmenopausal Women With Metastatic Breast Cancer [clinicaltrials:NCT00014638]Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions [clinicaltrials:NCT00029224]EPO906 Therapy in Patients With Advanced Colorectal Cancer [clinicaltrials:NCT00035087]EPO906 Therapy in Patients With Advanced Ovarian, Primary Fallopian, or Primary Peritoneal Cancer [clinicaltrials:NCT00035100]EPO906 Therapy in Patients With Prostate Cancer [clinicaltrials:NCT00035113]EPO906 Therapy in Patients With Advanced Breast Cancer [clinicaltrials:NCT00035126]EPO906 Therapy in Patients With Advanced Melanoma [clinicaltrials:NCT00035165]EPO906 Therapy in Patients With Advanced Kidney Cancer [clinicaltrials:NCT00035243]Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis [clinicaltrials:NCT00035997]A 12-week, Multicenter, Safety and Dose-ranging Study of 3 Oral Doses of TCH346 in Patients With Amyotrophic Lateral Sclerosis [clinicaltrials:NCT00036413]clinicaltrials:NCT00045942Evaluating the Ability of Zoledronic Acid to Reduce the Rate of Subsequent Osteoporotic Fractures After a Hip Fracture [clinicaltrials:NCT00046254]Efficacy and Safety of Omalizumab in Patients With Severe Persistent Asthma [clinicaltrials:NCT00046748]HORIZON-PFT: Pivotal Fracture Trial [clinicaltrials:NCT00049829]clinicaltrials:NCT00050011EPO906 in Carcinoid and Other Neuroendocrine Tumors [clinicaltrials:NCT00050349]STOP Trial - Sandostatin LAR Depot Trial for the Optimum Prevention of Chemotherapy Induced Diarrhea [clinicaltrials:NCT00050635]Pediatric Epilepsy Study [clinicaltrials:NCT00050934]Pediatric Epilepsy Study [clinicaltrials:NCT00050947]clinicaltrials:NCT00051636Treatment of Von Hippel-Lindau (VHL)-Related Hemangioblastoma With PTK787/ZK 222584 [clinicaltrials:NCT00052013]Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Previously Treated Metastatic Colorectal Cancer [clinicaltrials:NCT00056446]Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Metastatic Colorectal Cancer. [clinicaltrials:NCT00056459]A Randomized, Double Blind Trial of LdT (Telbivudine) Versus Lamivudine in Adults With Compensated Chronic Hepatitis B [clinicaltrials:NCT00057265]Safety & Efficacy of ICL670 vs. Deferoxamine in Beta-thalassemia Patients With Iron Overload Due to Blood Transfusions [clinicaltrials:NCT00061750]Study of Deferasirox in Iron Overload From Beta-thalassemia Unable to be Treated With Deferoxamine or Chronic Anemias [clinicaltrials:NCT00061763]Bisphosphonate Treatment of Osteogenesis Imperfecta [clinicaltrials:NCT00063479]The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy [clinicaltrials:NCT00063609]Safety of ICL670 vs. Deferoxamine in Sickle Cell Disease Patients With Iron Overload Due to Blood Transfusions [clinicaltrials:NCT00067080]Study Evaluating TCH346 and Placebo Administered Once Daily in Patients With Amyotrophic Lateral Sclerosis (ALS) [clinicaltrials:NCT00072709]clinicaltrials:NCT00076336
source [clinicaltrials_vocabulary:source]
Novartis [clinicaltrials_resource:4b711ffdbe8af5c8f3f9c53da46d83fa]
Bio2RDF identifier
4b711ffdbe8af5c8f3f9c53da46d83fa
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:4b711ffdbe8af5c8f3f9c53da46d83fa
organization [clinicaltrials_vocabulary:organization]
identifier
clinicaltrials_resource:4b711ffdbe8af5c8f3f9c53da46d83fa
title
Novartis
@en
type
label
Novartis [clinicaltrials_resource:4b711ffdbe8af5c8f3f9c53da46d83fa]
@en